I K U
Cart 0

I K U

A DECENTRALIZED RESEARCH ORGANIZATION

First mission: end alzheimer’s

Molecules2.png

 


 
 

THE IKU NEURODRO

IKU is the first decentralized research organization to tokenize a scientific breakthrough, a new BIOMARKER, that may end Alzheimer's Disease. We are the first to offer the IP and commercial royalty of a supplement addressing a $300 billion annual market in the USA alone. The NEURON token will represent your ownership and access to our first project, the IKU NeuroDRO.

 
 

The Scientific justification

 
 


More videos

 
 
 

Interesting...Tell me more

 

THE SOLUTION

IKU is a DRO - decentralized research organization - for funding and developing bio r&d, OPEN TO THE WORLD. The IKU architecture leverages blockchain to create global license markets for bio IP, and an A.I. Neural Network to derisk those markets. Our goal is to accelerate drug discovery and biotech innovation so we all can reap the benefits.

Pic-3.png
Pic4.png

MONEYBALL Strategy

We employ the Stanford University SPARK MONEYBALL strategy - driving undervalued r&D into the market - which has generated an additional 1,000% follow-on funding for SPARK funded r&d. SPARK prioritizes science, a complete 180 from the Big Pharma approach, and has generated unprecedented results. IKU has vetted this strategy with SPARK and its time for blast off.


HOW?

 
Access

ACCESS

  • Unlock IKU with our user token.

  • Access the crowd-fund, proposal, and development features.

  • Collaborate in a biotech digital commons.

EIP1048.png

Research

  • Crowdfund and commoditize your research.

  • Vet research with A.I. and Stanford SPARK.

  • License research and trade as a commodity.

Development Rights.png

Develop

  • Encrypt, store, and access r&d data on IPFS.

  • Enforce & monitor development.

  • Contribute to research.

Royalties.png

Earn

  • Earn royalties based on contributed work - Proof of Work.

  • Reward the IKU network for crowdfunding.

  • Create & service bounties.

 

Nobel Laureate interviews

 
LINDAU-LOGO-WHITE.png

IKU was a Principal Benefactor of the 2018 Lindau Nobel Laureate Meeting. We interviewed many of the Nobel Laureates and young scientists on controversial issues in the biotech space. You can listen to clips here.

 

TEAM

 
Gregory Rigano, Esq.     Founder & CEO    Experience: Stanford  SPARK Advisor,  Chadbourne & Park  LLP Associate

Gregory Rigano, Esq.

Founder & CEO

Experience: Stanford SPARK Advisor, Chadbourne & Park LLP Associate

ELI     Artificial Neural network    Experience:  I’m Learning. Speak soon...

ELI

Artificial Neural network

Experience: I’m Learning. Speak soon...

Michael Kisselgof

Project Lead & CoFounder

Experience: SAP Global Marketing, Credit Suisse Private Banking

Elias Wolf     ML Engineer    Experience: Porsche  Indoor Autonomous Security Drone

Elias Wolf

ML Engineer

Experience: Porsche Indoor Autonomous Security Drone

Tom Ding     Angel Investor    Experience: Dfinity  CoFOunder,  String Labs  CEO

Tom Ding

Angel Investor

Experience: Dfinity CoFOunder, String Labs CEO

Thomas Deisboeck MD     Bio-Innovation Advisor    Experience:  Associate Professor in Radiology,  Harvard  Medical School

Thomas Deisboeck MD

Bio-Innovation Advisor

Experience: Associate Professor in Radiology, Harvard Medical School

Andrew Phillips     Business Development Lead    Experience: Dfinity  NYC, Bonding Curves

Andrew Phillips

Business Development Lead

Experience: Dfinity NYC, Bonding Curves

IKUTEER     Lead Software Engineer    Experience:  Lead engineer, app w/ $100M revenue/year, Senior Engineer Web 3.0

IKUTEER

Lead Software Engineer

Experience: Lead engineer, app w/ $100M revenue/year, Senior Engineer Web 3.0

 
 
 
 
 
 

PRESS

 
 

 Mission

IKU is solving for an illiquid, centralized, and broken R&D model that is silo’d and closed to the public. IKU gives you the opportunity to sponsor and accelerate bio innovation.

Molecules2.png

 

Subscribe

 Sign up with your email address to receive news and updates.